• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物遗传学在优化甲氨蝶呤治疗银屑病中的应用潜力。

The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.

作者信息

Warren R B, Griffiths C E M

机构信息

Department of Dermatology, Royal Liverpool and Broadgreen Hospital, Liverpool L14 3LB, UK.

出版信息

Br J Dermatol. 2005 Nov;153(5):869-73. doi: 10.1111/j.1365-2133.2005.06880.x.

DOI:10.1111/j.1365-2133.2005.06880.x
PMID:16225593
Abstract

The study of pharmacogenetics will optimize the use of systemic therapies in dermatology. Directed prescription of azathioprine dependent on phenotypic expression of the thiopurine methyltransferase gene is now accepted practice. To some extent other, older drugs have been neglected. We look at the role that pharmacogenetics could play in the use of methotrexate for psoriasis, focusing on known polymorphisms in the folate metabolic pathway.

摘要

药物遗传学的研究将优化皮肤病学中全身治疗的应用。根据硫嘌呤甲基转移酶基因的表型表达来指导硫唑嘌呤的处方现已成为公认的做法。在某种程度上,其他较老的药物则被忽视了。我们探讨了药物遗传学在甲氨蝶呤治疗银屑病中的作用,重点关注叶酸代谢途径中已知的基因多态性。

相似文献

1
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.药物遗传学在优化甲氨蝶呤治疗银屑病中的应用潜力。
Br J Dermatol. 2005 Nov;153(5):869-73. doi: 10.1111/j.1365-2133.2005.06880.x.
2
Folate supplementation during methotrexate therapy for patients with psoriasis.银屑病患者甲氨蝶呤治疗期间补充叶酸。
J Am Acad Dermatol. 2005 Oct;53(4):652-9. doi: 10.1016/j.jaad.2005.06.036.
3
Methotrexate for psoriasis: current European practice. A postal survey.甲氨蝶呤治疗银屑病:欧洲当前的实践。一项邮寄问卷调查。
J Eur Acad Dermatol Venereol. 2005 Mar;19(2):196-202. doi: 10.1111/j.1468-3083.2004.01140.x.
4
Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis.叶酸、嘧啶和嘌呤代谢中的多态性与甲氨蝶呤治疗银屑病的疗效和毒性相关。
J Invest Dermatol. 2007 Aug;127(8):1860-7. doi: 10.1038/sj.jid.5700808. Epub 2007 Apr 5.
5
Pharmacogenomics and the resulting impact on psoriasis therapies.药物基因组学及其对银屑病治疗的影响。
Dermatol Clin. 2015 Jan;33(1):149-60. doi: 10.1016/j.det.2014.09.011.
6
[Individual monitoring of thiopurine and methotrexate treatment].[硫唑嘌呤和甲氨蝶呤治疗的个体监测]
Ugeskr Laeger. 2005 May 16;167(20):2177-9.
7
How genetic variation affects patient response and outcome to therapy for psoriasis.遗传变异如何影响银屑病患者对治疗的反应和结局。
Expert Rev Clin Immunol. 2010 Nov;6(6):957-66. doi: 10.1586/eci.10.74.
8
[Prescription and surveillance of treatment by a systemic agent or biotherapy in psoriasis].[银屑病全身用药或生物治疗的处方及治疗监测]
Ann Dermatol Venereol. 2010 Apr;137(4 Suppl):8-12. doi: 10.1016/S0151-9638(10)70011-9.
9
Pharmacogenetics of folate-related drug targets in cancer treatment.癌症治疗中叶酸相关药物靶点的药物遗传学
Pharmacogenomics. 2005 Oct;6(7):673-89. doi: 10.2217/14622416.6.7.673.
10
Increased insulin-like growth factor binding protein-3 expression level in psoriatic tissue before and after systemic treatment with cyclosporine A and methotrexate.
Int J Dermatol. 2008 Nov;47(11):1177-83. doi: 10.1111/j.1365-4632.2008.03810.x.

引用本文的文献

1
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.HLA-C*06:02在银屑病患者长期使用阿达木单抗治疗后不会导致临床反应:一项回顾性队列研究。
Mol Diagn Ther. 2017 Jun;21(3):295-301. doi: 10.1007/s40291-017-0261-4.
2
Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis.优特克单抗治疗银屑病和银屑病关节炎。
Rheumatol Ther. 2015 Jun;2(1):1-16. doi: 10.1007/s40744-015-0010-2. Epub 2015 Mar 17.
3
Dermatology: future therapeutic perspectives.
皮肤病学:未来的治疗前景。
Dermatol Ther (Heidelb). 2013 Dec;3(2):115-6. doi: 10.1007/s13555-013-0037-7. Epub 2013 Dec 3.